A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2‐73) Phase 2a clinical study

202078 citationsJournal Articlegold Open Access

Authors

Harald Hampel · Pitié-Salpêtrière Hospital

Coralie Williams · Institut Supérieur des Études Technologiques en Communications de Tunis

Adrien Etcheto · Institut Supérieur des Études Technologiques en Communications de Tunis

Federico Goodsaid · Clinical Research Puerto Rico

Frédéric Parmentier · Institut Supérieur des Études Technologiques en Communications de Tunis

Jean Sallantin · Laboratoire d'Informatique, de Robotique et de Microélectronique de Montpellier

Abstract

Confirmatory Phase 2b/3 clinical studies of these patient selection markers are ongoing. This FCA/KEM analysis is a template for the identification of patient selection markers in early therapeutic development for neurologic disorders.

Topics & Keywords

Pharmacological Receptor Mechanisms and Effects Computational Drug Discovery Methods Neuropeptides and Animal Physiology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Alzheimer s & Dementia Translational Research & Clinical Interventions

Volume 6, Issue 1, pp. e12013-e12013

DOI: 10.1002/trc2.12013

Field-Weighted Citation Impact: 3.89